Literature DB >> 21350834

Levels and determinants of exposure to vapours and aerosols of bitumen.

Anne Spickenheuer1, Reinhold Rühl, Dieter Höber, Monika Raulf-Heimsoth, Boleslaw Marczynski, Peter Welge, Dietmar Breuer, Stefan Gabriel, Uwe Musanke, Peter Rode, Evelyn Heinze, Benjamin Kendzia, Rainer Bramer, Udo Knecht, Jens-Uwe Hahn, Thomas Brüning, Beate Pesch.   

Abstract

Bitumen (referred to as asphalt in the United States) is a widely used construction material, and emissions from hot bitumen applications have been a long-standing health concern. One objective of the Human Bitumen Study was to identify potential determinants of the exposure to bitumen. The study population analysed comprised 259 male mastic asphalt workers recruited between 2003 and 2008. Personal air sampling in the workers' breathing zone was carried out during the shift to measure exposure to vapours and aerosols of bitumen. The majority of workers were engaged in building construction, where exposure levels were lower than in tunnels but higher than at road construction sites. At building construction sites, exposure levels were influenced by the room size, the processing temperature of the mastic asphalt and the job task. The results show that protective measures should include a reduction in the processing temperature.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21350834     DOI: 10.1007/s00204-011-0677-2

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  2 in total

1.  Metabolites of the PAH diol epoxide pathway and other urinary biomarkers of phenanthrene and pyrene in workers with and without exposure to bitumen fumes.

Authors:  Anne Lotz; Beate Pesch; Gerhard Dettbarn; Monika Raulf; Peter Welge; Hans-Peter Rihs; Dietmar Breuer; Stefan Gabriel; Jens-Uwe Hahn; Thomas Brüning; Albrecht Seidel
Journal:  Int Arch Occup Environ Health       Date:  2016-08-10       Impact factor: 3.015

2.  The Human Bitumen Study.

Authors:  C van Thriel; R Marchan
Journal:  EXCLI J       Date:  2012-11-06       Impact factor: 4.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.